AstraZeneca PLC (AZN)vsIdeaya Biosciences Inc (IDYA)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
IDYA
Ideaya Biosciences Inc
$28.05
-3.41%
HEALTHCARE · Cap: $2.46B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 26757% more annual revenue ($58.74B vs $218.71M). AZN leads profitability with a 17.4% profit margin vs -52.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
IDYA
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+80.2%
Fair Value
$160.75
Current Price
$28.05
$132.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 55.4% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
ROE of -10.9% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : IDYA
The strongest argument for IDYA centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 55.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : IDYA
The primary concerns for IDYA are EPS Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
AZN profiles as a value stock while IDYA is a hypergrowth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.28 — expect wider price swings.
IDYA is growing revenue faster at 55.4% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 35/100), backed by strong 17.4% margins. IDYA offers better value entry with a 80.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Ideaya Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?